GSTM1 and Neurodevelopmental delay: These real-world findings are consistent with phase 3 data from PRO2TECT, where vadadustat was non-inferior to darbepoetin alfa for maintaining hemoglobin in NDD patients [30] and with earlier phase 2 trials that demonstrated robust dose-dependent Hb increases [33].